Last updated: February 20, 2026
Lithobid (lithium carbonate) is a branded lithium-based medication used primarily to treat bipolar disorder. It is manufactured by multiple suppliers, including the originator company and generic manufacturers.
Major Suppliers of Lithobid
1. Eli Lilly and Company
- Role: Original patent holder and producer of Lithobid.
- Market Status: Manufacturing until patent expiration in 2018.
- Current Production: No longer produces Lithobid, with focus shifted to generics. Certificates of Manufacture from Eli Lilly are unavailable for new batches post-2018.
2. Generic Manufacturers
Following patent expiration, multiple manufacturers began producing lithium carbonate under generic names, supplying hospitals, pharmacies, and compounding pharmacies globally.
| Manufacturer |
Product Name |
Approval Status |
Manufacturing Locations |
Estimated Production Capacity |
| Prasco Labs |
Lithium Carbonate USP |
FDA-approved (U.S. market) |
United States |
~10 million tablets/month |
| Aurobindo Pharma |
Lithium Carbonate |
Approved in the U.S., EU, other regions |
India, EU facilities |
Unknown, but significant |
| Teva Pharmaceutical Industries |
Lithium Carbonate |
Approved in multiple regions |
Israel, globally manufacturing |
Large-scale |
| Sandoz (Novartis) |
Lithium Carbonate |
Approved |
Multiple global locations |
Substantial |
| Mylan (now part of Viatris) |
Lithium Carbonate |
Global approval |
Multiple manufacturing sites |
Large-scale |
Sources of Manufacturing Data
- U.S. Food and Drug Administration (FDA) Orange Book
- European Medicines Agency (EMA)
- Company Annual Reports and press releases
- Industry databases (e.g., IQVIA)
Distribution Channels
- Pharmaceutical Wholesalers: Major players like McKesson, Cardinal Health, and AmerisourceBergen distribute lithium carbonate to pharmacies.
- Compounding Pharmacies: Purchase bulk API or available tablets for custom formulations.
- Direct Purchase: Large pharmaceutical companies and hospitals may order directly from manufacturers.
Geographical Supply Considerations
- United States: Dominated by U.S. FDA-approved generics, primarily from Prasco, Aurobindo, Teva, Sandoz, and Mylan.
- Europe: Multiple EU-approved generics, with some manufacturers holding centralized approval.
- Asia: Significant production capacity from Indian and Chinese API manufacturers, with exports to global markets.
Regulatory and Patent Status
- The original patent held by Eli Lilly expired in 2018.
- Generic manufacturers obtained approval based on bioequivalence studies.
- Ongoing patent litigations are not reported for lithium carbonate; thus, multiple sources operate concurrently.
Key Takeaways
- Lithobid was originally produced by Eli Lilly until patent expiration in 2018.
- Multiple generic manufacturers supply lithium carbonate with FDA approval in the U.S. and equivalents elsewhere.
- Capacity and pricing vary depending on the manufacturer and region.
- Distribution through wholesalers and direct channels meets global demand.
FAQs
What companies produce lithium carbonate?
Multiple firms, including Aurobindo, Teva, Sandoz, and Mylan, manufacture approved lithium carbonate products.
Are there differences between branded and generic lithium carbonate?
Yes. Branded Lithobid was produced solely by Eli Lilly. Generics meet bioequivalence standards, but differences in excipients or manufacturing processes may exist.
Is lithium carbonate available globally?
Yes. Approved manufacturers supply in North America, Europe, and Asia, with distribution channels worldwide.
What is the primary regulation for lithium carbonate?
In the U.S., the FDA approves generics via the Abbreviated New Drug Application (ANDA) pathway. Other regions follow their respective regulatory standards.
Can generic lithium carbonate be substituted for Lithobid?
Yes, provided it meets the same bioequivalence standards and approval requirements. Physicians and pharmacists determine substitution based on clinical considerations.
Citations
[1] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency. (2023). List of medicines authorized in the European Union.
[3] Eli Lilly and Company. (2018). Patent expiry announcement for Lithobid.
[4] IQVIA. (2023). Global Pharmaceutical Market Data.
[5] Mylan. (2022). Annual Report and Product Portfolio.
